TY - JOUR
T1 - Interaction between high-density lipoproteins and inflammation
T2 - Function matters more than concentration!
AU - Nazir, Sumra
AU - Jankowski, Vera
AU - Bender, Guzide
AU - Zewinger, Stephen
AU - Rye, Kerry-Anne
AU - van der Vorst, Emiel P. C.
N1 - Funding Information:
This work is supported by a grant from the Interdisciplinary Center for Clinical Research within the faculty of Medicine at the RWTH Aachen University , the DZHK ( German Centre for Cardiovascular Research ) and the BMBF ( German Ministry of Education and Research ), and NWO-ZonMw Veni ( 91619053 ) to E.P.C.v.d.V; by the DFG ( SFB/TRR219-TP-C09 ) to S.Z. and ( SFB/TRR219-TP-S03 ) to V.J.
Publisher Copyright:
© 2020 The Authors
PY - 2020
Y1 - 2020
N2 - High-density lipoprotein (HDL) plays an important role in lipid metabolism and especially contributes to the reverse cholesterol transport pathway. Over recent years it has become clear that the effect of HDL on immune modulation is not only dependent on HDL concentration but also and perhaps even more so on HDL function. This review will provide a concise general introduction to HDL followed by an overview of post-translational modifications of HDL and a detailed overview of the role of HDL in inflammatory diseases. The clinical potential of HDL and its main apolipoprotein constituent, apoA-I, is also addressed in this context. Finally, some conclusions and remarks that are important for future HDL-based research and further development of HDL-focused therapies are discussed. (C) 2020 The Author(s). Published by Elsevier B.V.
AB - High-density lipoprotein (HDL) plays an important role in lipid metabolism and especially contributes to the reverse cholesterol transport pathway. Over recent years it has become clear that the effect of HDL on immune modulation is not only dependent on HDL concentration but also and perhaps even more so on HDL function. This review will provide a concise general introduction to HDL followed by an overview of post-translational modifications of HDL and a detailed overview of the role of HDL in inflammatory diseases. The clinical potential of HDL and its main apolipoprotein constituent, apoA-I, is also addressed in this context. Finally, some conclusions and remarks that are important for future HDL-based research and further development of HDL-focused therapies are discussed. (C) 2020 The Author(s). Published by Elsevier B.V.
KW - High-density lipoproteins
KW - Inflammation
KW - Metabolic diseases
KW - Infectious diseases
KW - Auto-immune diseases
KW - Neurological diseases
KW - Chronic kidney disease
KW - APOLIPOPROTEIN-A-I
KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS
KW - ESTER TRANSFER PROTEIN
KW - CHOLESTEROL EFFLUX CAPACITY
KW - ATHEROGENIC LIPID PROFILE
KW - TYPE-2 DIABETES-MELLITUS
KW - CORONARY-ARTERY-DISEASE
KW - EXTENDED-RELEASE NIACIN
KW - ALTERS HDL COMPOSITION
KW - ACUTE LUNG INJURY
U2 - 10.1016/j.addr.2020.10.006
DO - 10.1016/j.addr.2020.10.006
M3 - (Systematic) Review article
C2 - 33080259
SN - 0169-409X
VL - 159
SP - 94
EP - 119
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -